The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
SARS-coronavirus replication in human peripheral monocytes/macrophages
Open accessAbstract
A novel coronavirus (CoV) has been described in association with cases of severe acute respiratory syndrome (SARS). The virus, SARS-CoV, differs from the previously described human coronaviruses, 229E and OC43. 229E was previously shown to productively infect human monocytes/macrophages, whereas OC43 poorly infected the cells. In this study, we examined whether SARS-CoV could productively infect purified monocytes/macrophages (PM) derived from human donor cells. Unlike 229E-infected cells, which produced viral titers of 103.5 to 106 TCID50/ml, SARS-CoV replicated poorly in PM, producing titers of 101.75 to 102 TCID50/ml. This finding was similar to results reported for OC43-infected cells, with titers ranging from 101.2 to 102.7 TCID50/ml. Of interest, SARS-CoV proteins were detected only in PM that did not produce significant amounts of interferon (IFN)-α, and in one such case, preliminary electron microscope studies demonstrated that SARS-CoV-like particles could enter the cells, possibly via phagocytosis. These results suggest that SARS-CoV, like human CoV OC43, poorly infects human PM, and production of IFN-α by these cells further limits the infection. Given the importance of monocytes/macrophages to the immune response, it is possible that their infection by SARS-CoV and alteration of this infection by IFN-α may be important to the course of the infection in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus
Li, W., Moore, M. J., Vasilieva, N., Sui, J., Wong, S. K., Berne, M. A., Somasundaran, M., Sullivan, J. L., Luzuriaga, K., Greenough, T. C., et al. (2003) · Nature · doi:10.1038/nature02145 · Cited by 5,923
Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme
Harmer, D., Gilbert, M., Borman, R., & Clark, K. L. (2002) · FEBS Letters · doi:10.1016/s0014-5793(02)03640-2 · Cited by 852
Circulating, Interferon‐Producing Plasmacytoid Dendritic Cells Decline During Human Ageing
Shodell, M., & Siegal, F. P. (2002) · Scandinavian Journal of Immunology · doi:10.1046/j.1365-3083.2002.01148.x · Cited by 189 · cited 2×
“It is known that IFN-␣ levels are highest in the young and decrease with age (Katschinski et al., 1994; Shodell and Siegal, 2002) .”
Background
Cited by
The trinity of COVID-19: immunity, inflammation and intervention
Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0311-8 · Cited by 4,360
Korber, B., Fischer, W. M., Gnanakaran, S., Yoon, H., Theiler, J., Abfalterer, W., Hengartner, N., Giorgi, E. E., Bhattacharya, T., Foley, B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.06.043 · Cited by 4,281
Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19
Silvin, A., Chapuis, N., Dunsmore, G., Goubet, A.-G., Dubuisson, A., Derosa, L., Almire, C., Hénon, C., Kosmider, O., Droin, N., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.002 · Cited by 834
Coronavirus Disease 2019: Coronaviruses and Blood Safety
Chang, L., Yan, Y., & Wang, L. (2020) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2020.02.003 · Cited by 659
Immunopathogenesis of coronavirus infections: implications for SARS
Dandekar, A. A., & Perlman, S. (2005) · Nature Reviews Immunology · doi:10.1038/nri1732 · Cited by 499
A perspective on potential antibody-dependent enhancement of SARS-CoV-2
Arvin, A. M., Fink, K., Schmid, M. A., Cathcart, A., Spreafico, R., Havenar-Daughton, C., Lanzavecchia, A., Corti, D., & Virgin, H. W. (2020) · Nature · doi:10.1038/s41586-020-2538-8 · Cited by 485
Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins
Wang, S.-F., Tseng, S.-P., Yen, C.-H., Yang, J.-Y., Tsao, C.-H., Shen, C.-W., Chen, K.-H., Liu, F.-T., Liu, W.-T., Chen, Y.-M. A., et al. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.07.090 · Cited by 421
Control of coronavirus infection through plasmacytoid dendritic-cell–derived type I interferon
Cervantes-Barragan, L., Züst, R., Weber, F., Spiegel, M., Lang, K. S., Akira, S., Thiel, V., & Ludewig, B. (2007) · Blood · doi:10.1182/blood-2006-05-023770 · Cited by 397
Zhang, D., Guo, R., Lei, L., Liu, H., Wang, Y., Wang, Y., Qian, H., Dai, T., Zhang, T., Lai, Y., et al. (2021) · Journal of Leukocyte Biology · doi:10.1002/jlb.4hi0720-470r · Cited by 383
Corman, V. M., Albarrak, A. M., Omrani, A. S., Albarrak, M. M., Farah, M. E., Almasri, M., Muth, D., Sieberg, A., Meyer, B., Assiri, A. M., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/civ951 · Cited by 374
Jafarzadeh, A., Chauhan, P., Saha, B., Jafarzadeh, S., & Nemati, M. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118102 · Cited by 327
Lessons for COVID-19 immunity from other coronavirus infections
Sariol, A., & Perlman, S. (2020) · Immunity · doi:10.1016/j.immuni.2020.07.005 · Cited by 317
Qian, Z., Travanty, E. A., Oko, L., Edeen, K., Berglund, A., Wang, J., Ito, Y., Holmes, K. V., & Mason, R. J. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2012-0339oc · Cited by 315
Jaume, M., Yip, M. S., Cheung, C. Y., Leung, H. L., Li, P. H., Kien, F., Dutry, I., Callendret, B., Escriou, N., Altmeyer, R., et al. (2011) · Journal of Virology · doi:10.1128/jvi.00671-11 · Cited by 314
In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies
Li, D., Edwards, R. J., Manne, K., Martinez, D. R., Schäfer, A., Alam, S. M., Wiehe, K., Lu, X., Parks, R., Sutherland, L. L., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.021 · Cited by 287
COVID-19 outbreak: history, mechanism, transmission, structural studies and therapeutics
Yesudhas, D., Srivastava, A., & Gromiha, M. M. (2021) · Infection · doi:10.1007/s15010-020-01516-2 · Cited by 270
Monocytes and Macrophages in COVID-19
Knoll, R., Schultze, J. L., & Schulte-Schrepping, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.720109 · Cited by 266
SARS-CoV-2 infection, COVID-19 pathogenesis, and exposure to air pollution: What is the connection?
Woodby, B., Arnold, M. M., & Valacchi, G. (2021) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14512 · Cited by 160
Alquisiras-Burgos, I., Peralta-Arrieta, I., Alonso-Palomares, L. A., Zacapala-Gómez, A. E., Salmerón-Bárcenas, E. G., & Aguilera, P. (2021) · Molecular Neurobiology · doi:10.1007/s12035-020-02134-7 · Cited by 115
“DAMPs are endogenous molecules released from damaged cells that interact with molecules called pattern-recognition receptor (PRR) that induce in the neighboring epithelial cells, endothelial cells, and macrophages a state of high inflammation [109].”
BackgroundAhmed-Hassan, H., Sisson, B., Shukla, R. K., Wijewantha, Y., Funderburg, N. T., Li, Z., Hayes, D., Demberg, T., & Liyanage, N. P. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01979 · Cited by 47
Metadata
- Authors
- Yilla, M., Harcourt, B. H., Hickman, C. J., McGrew, M., Tamin, A., Goldsmith, C. S., Bellini, W. J., & Anderson, L. J.
- Venue
- Virus Research
- Publisher
- Elsevier BV
- Published
- 2005-01
- Volume
- 107
- Issue
- 1
- Pages
- 93-101
- ISSN
- 0168-1702 (ISSN-L)
- OpenAlex
- W1966929320
- Cited by
- 190
- References
- 3
- FWCI
- 2.33
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.